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Background: The loss of tumor suppressor gene (TSG) function is a critical step in the pathogenesis of human lung
cancer. RBM5 (RNA-binding motif protein 5, also named H37/LUCA-15) gene from chromosome 3p21.3
demonstrated tumor suppressor activity. However, the role of RBM5 played in the occurrence and development of
lung cancer is still not well understood.
Method: Paired non-tumor and tumor tissues were obtained from 30 adenocarcinomas. The expression of RBM5
mRNA and protein was examined by RT-PCR and Western blot. A549 cell line was used to determine the apoptotic
function of RBM5 in vitro. A549 cells were transiently transfected with pcDNA3.1-RBM5. AnnexinV analysis was
performed by flow cytometry. Expression of Bcl-2, cleaved caspase-3, caspase-9 and PAPP proteins in A549 lung
cancer cells and the A549 xenograft BALB/c nude mice model was determined by Western blot. Tumor suppressor
activity of RBM5 was also examined in the A549 xenograft model treated with pcDNA3.1-RBM5 plasmid carried by
attenuated Salmonella typhi Ty21a.
Result: The expression of RBM5 mRNA and protein was decreased significantly in adenocarcinoma tissues
compared to that in the non-tumor tissues. In addition, as compared to the vector control, a significant growth
inhibition of A549 lung cancer cells was observed when transfected with pcDNA3.1-RBM5 as determined by cell
proliferation assay. We also found that overexpression of RBM5 induced both early and late apoptosis in A549 cells
using AnnexinV/PI staining as determined by flow cytometry. Furthermore, the expression of Bcl-2 protein was
decreased, whereas the expression of cleaved caspase-3, caspase-9 and PARP proteins was significantly increased in
the RBM5 transfected cells; similarly, expression of decreased Bcl-2 and increased cleaved caspase-3 proteins was
also examined in the A549 xenograft model. More importantly, we showed that accumulative and stable
overexpression of RBM5 in the A549 xenograft BALB/c nude mice model significantly inhibited the tumor growth
rate in vivo as compared to that in the control.
Conclusion: Our study demonstrates that RBM5 can inhibit the growth of lung cancer cells and induce apoptosis
both in vitro and in vivo, which suggests that RBM5 might be used as a potential biomarker or target for lung
cancer diagnosis and chemotherapy. Moreover, we propose a novel animal model set up in BALB/c nude mice
treated with attenuated Salmonella as a vector carrying plasmids to determine RBM5 function in vivo.
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Lung cancer is the leading cause of cancer death world-
wide, with over a million deaths annually [1,2]. Lung
cancer is classified into two major clinic-pathological
groups, small cell lung carcinoma (SCLC) and non-small
cell lung carcinoma (NSCLC). Squamous cell carcinoma,
adenocarcinoma and large cell carcinoma are the major
histologic types of NSCLC [3]. The proportion of lung
adenocarcinoma in lung cancer has risen rapidly, which
becomes the major pathological type with morbidity of
30%-40% of all lung cancer types [4]. Although tobacco
smoking was considered as one of the key factors in pro-
moting this devastating malignancy [5], the acquired
genetic or epigenetic changes also played an important
role in the occurrence and development of lung cancer.
Deletion within the lung cancer tumor suppressor re-
gion at chromosome 3p21.3 constitutes the earliest pre-
malignant chromosomal aberration in human lung
cancers [6]. The region of most frequent chromosomal
deletion found at the earliest stage in lung cancer devel-
opment houses 19 genes [7], many of which may act to-
gether as a ‘tumor suppressor group,’ representing one of
the most promising opportunities for development of
new diagnostic/prognostic and therapeutic target for
lung cancer as well as for many other types of malignan-
cies [8,9]. RNA binding motif 5 (RBM5, also called
Luca15 or H37 [10,11]) maps to one end of this 19-gene
deletion breakpoint, which is common to lung, breast
and renal tumors [12].
At present, studies on the link of RBM5 and lung can-
cer are mainly confined to the cell lines. Most studies
showed that the expression of RMB5 on cancer cells was
virtually similar to that on the non-cancer cells. The
possible reasons for this might be due to the long period
of in vitro fostering and the changes of genetic expres-
sion [8,13,14]. Few studies on the expression and func-
tion of RBM5 on lung cancer tissues, especially on the
tissues of primary lung adenocarcinoma, could be found
[11,15,16]. Two groups examined the RBM5 expression
on a small number of lung cancer tissues and found that
most lung cancer, except a large cell carcinoma subtype
that showed higher RBM5 expression, had remarkably
lower expression of RBM5 [11,15]. In this study, we
examined the RBM5 expression on 30 samples of lung
adenocarcinoma patients in the hope to better under-
stand the role and function of this cancer suppressor in
the fostering and growing of lung adenocarcinoma.
RBM5 is an RNA-binding protein that has the ability
to modulate apoptosis [17-19]. Overexpression of RBM5
sensitizes cells to certain apoptotic stimuli and induces
apoptosis [17]. In addition, overexpression of RBM5,
which is also involved in the regulation of alternative
splicing, was shown to inhibit tumor growth and
reduced the metastatic potential [9,20].To further investigate the mechanism behind this
modulation and sensitization process, we examined the
expression of key apoptosis-associated genes in RBM5-
overexpressing lung cancer cells. Our results showed
that RBM5 significantly inhibited the growth of A549
cells both in vitro and in vivo, and induced apoptosis by
increasing expression of cleaved caspase-3, caspase-9
and PARP proteins and reducing expression of Bcl-2
protein. Moreover, we propose a novel animal model set
up in BALB/c nude mice treated with attenuated
Salmonella as a vector carrying plasmids to determine
RBM5 function in vivo.Methods
Specimen collection
This study was approved by the Institutional Review
Board of the Second Affiliated Hospital of Jilin Univer-
sity, Changchun, China. Thirty pairs of tissues and the
information of disease history were collected from the
patients, who had been diagnosed with primary lung
adenocarcinoma. All participants underwent surgery and
provided written informed consent. Samples were snap-
frozen in liquid nitrogen at the time of study and stored
at −80°C until RNA or protein was extracted following
the routine protocol. All cases were reevaluated by
pathologists for confirming tumor histology and tumor
content.Cell culture
A549 cell line was purchased from the American Tissue
Type Collection (Manassas, VA). Cells were grown in
RPMI 1640 supplemented with 10% fetal bovine serum
as previously described [21].Transfections
A549 cells were transiently transfected with pcDNA3.1
or pcDNA3.1-RBM5 plasmids using the Lipofectamine
2000 reagent (Roche, Switzerland) for the indicated
times according to the manufacturer’s instruction.
Briefly, 1 × 105 cells were seeded into six-well plates
containing an antibiotic-free medium and incubated
overnight. For each well, 2 μg DNA (pcDNA3.1 or
pcDNA3.1-RBM5) was mixed with 95 μl RPMI-1640
with 10% fetal bovine serum. The mixture was then
combined with a solution of 5 μl Lipofectamine (Roche,
Switzerland) in 95 μl RPMI-1640 with 10% fetal bovine
serum. After a 20-min incubation period at room
temperature, the mixture was applied to the cells in an
appropriate volume of OPTI-MEM I so as to achieve a
final volume of 2 ml. Then the cells were cultured for
an additional 24 h/48 h at 37°C before analysis.
Figure 1 Expression of RBM5 in human lung cancer tissues. (A) Agarose gel of semi-quantitative RT-PCR data of RBM5 mRNA expression in
representative samples from tumor and non-tumor specimens. Total RNA was isolated and subjected to semi-quantitative RT-PCR and quantified
using Quantity One software. (B) Western blot of RBM5 protein expression in representative samples from tumor and non-tumor specimens. Total
cellular protein was extracted, subjected to Western blot analysis and quantified using Quantity One software. (C) The ratio of RBM5 mRNA
expression level in normal lung tissues (N) to that in lung adenocarcinoma tissues (T). *χ2= 2.814, p< 0.05 indicates significant difference as
compared to the groups whose ratio > 1. (D) The ratio of RBM5 protein expression level in non-tumor tissue (N) to that in lung adenocarcinoma
tissues (T) from 30 patients with lung adenocarcinoma. *χ2 = 2.963, p< 0.05 indicates significant difference as compared to the groups whose
ratio > 1.
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Cell proliferation assay was evaluated using MTT accord-
ing to the manufacturer’s instruction. Briefly, A549 cells
transfected with pcDNA3.1 or pcDNA3.1-RBM5 plasmids
were seeded in a 96-well plate at a density of 1 × 104 cells
per well (0 hour). At 24 h and 48 h, 20 μl of 5 mg/ml
MTT in PBS was added, and the cells were subsequently
incubated for 4 h at 37°C in 5% CO2. Cells were then
washed twice with PBS, and the precipitate was solubi-
lized in 150 μl of 100% dimethylsulfoxide (Sigma, USA)
by shaking for 5 min. Absorbance was measured using
a microplate reader (Bio-Rad, Richmond, CA) at a
wavelength of 570 nm. All experiments were carried
out in triplicate.
Reverse transcription-polymerase chain reaction (RT- PCR)
Total RNAs were isolated using Trizol (Invitrogen, USA)
according to the manufacturer’s instruction. Reverse
transcription was performed with 3 μg of total RNA at a
final volume of 10 μl, containing 10 mM dNTP, 0.5 μg
oligo dT, 20 U RNasin and 200 U M-MLV reverse tran-
scriptase (Promega Corp., USA). The primer sequences
were RBM5: 5′-GCACGACTATAGGCATGACAT-3′ and
5′-AGTCAAACTTGTCTGCTCCA-3′, GAPDH: 5′-GAA
GGTGAAGGTCGGAGTC3′ and 5′-GAAGATGGTGAT
GGGATTTC-3′. PCR was performed at 95°C for 3 minand 25–30 cycles of 95°C for 30 s, 55°C for 30 s, 72°C
for 1 min and 72°C for 10 min. All densitometry scan-
ning was carried out using ImageMaster VDS Software
(Pharmacia Biotech, USA).
Protein extraction and Western blot
Total cellular proteins from both lung tissues and A549
cells were extracted according to the previous study
[22]. Protein samples (50 ug) were then separated by
SDS-PAGE and transferred onto a PVDF membrane
(Millipore, Bedford, MA). The primary antibodies were
rabbit anti-human RBM5, Bcl-2, PARP, cleaved-PARP,
caspase-3, cleaved caspase-3 and β-actin antibodies from
Abcam (MA, USA). The primary antibodies of rabbit
anti-human caspase-9 and cleaved caspase-9 antibodies
were from Cell Signaling Technology (USA). The second
antibody was a goat anti-rabbit IgG-HRP from Santa
Cruz Biotechnology (CA, USA). Western blot was car-
ried out as previously described [22]. The protein bands
were visualized by SuperSignal West Pico Chemilumin-
escent Substrate (Pierce, Rockford, IL, USA), and the
membranes were subjected to X-ray autoradiography.
Band intensities were determined with Quantity One
software (Bio-Rad, Hercules, CA, USA). Furthermore,
we confirmed the reproducibility of the experiments at
least three times.
Figure 2 Overexpression of RBM5 in A549 cells. A549 cells were
transfected with pcDNA3.1 or pcDNA3.1 RBM5 plasmids for 48 h. RT-
PCR and Western blot were performed respectively to determine the
RBM5 mRNA (A) and protein levels (B). Data shown are means ± SD
of three separate experiments (C). *Significant difference as
compared to the control (p< 0.01).
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A549 cells were transfected with pcDNA3.1 or
pcDNA3.1-RBM5 plasmids using the Lipofectamine
2000 reagent (Roche, Switzerland) for 48 h, followed by
harvesting, counting (1 × 106 cells) and resuspending in
100 μl of phosphate-buffered saline (PBS). Afterward,
5 μl of AnnexinV (1 μg/ml) (Beckman Coulter, Fullerton,
CA) was added and incubated at RT for 15 min, then
10 μl of propidium iodide (PI 1 μg/ml) was added and
incubated for additional 5 min at room temperature in
the dark. Finally, the cells were subjected to flow cyto-
metry (FCM) to measure the apoptosis rate with an
Epics-XL-MCL flow cytometer (Beckman Coulter, USA).Tumor growth analysis in A549 Xenograft
The models of A549 xenografts were established using
BALB/c nude mice (6 weeks old) that were acquired
from the Institute of Zoology, Chinese Academy of
Sciences (Beijing, China). Use of animals was in accord-
ance with Animal Care guidelines, and the protocol was
approved by Jilin University Animal Care Committee. Cul-
tured cells were washed and resuspended in phosphate-buffered saline (PBS). The suspension (5× 106 cells in
150 μl/ per mouse) was inoculated subcutaneously into
the right flanks of nude mice. The sizes of the tumors
were measured starting from day 7 after cell injection
until day 21 using calipers. These tumor-bearing mice
were then divided randomly into two groups (six mice per
group): (1) PcDNA3.1 as the control group; (2)
pcDNA3.1-RBM5 as the RBM5 group. Plasmids were car-
ried by bioengineered attenuated strains of Salmonella
enterica serovar typhimurium using electrotransfection as
previously described [22,23]. Briefly, plasmids were elec-
trotransfected into Salmonella typhi Ty21a competent
cells before use. Mice in each of these groups were inocu-
lated with bacteria with control vector (pcDNA3.1) or
pcDNA3.1-RBM5 plasmids [108 colony-forming units
(CFU) per 50 μl] via tail vein injection two times (on day
28 and 35). Tumors were measured using calipers every 4
days for 42 days in total, and the data were plotted using
the Kaplan-Meier method to analyze the tumor growth
curves. In addition, the wet weight and sizes of tumors
were measured when mice were killed. To ensure the
tumor-preferable distribution of the bacteria, an additional
pilot study was performed before the above-described ani-
mal experiments. Tissue samples of the primary tumor,
liver, lung, spleen, heart and kidney from mice were used
for bacterial distribution analysis on day 3 and 7 after in-
jection of attenuated Salmonella carrying plasmid. Equal
amounts of tissues were collected, minced, and homoge-
nized. Afterward, the homogenized tissues were plated in
triplicate onto Luria-Bertani agar containing ampicillin
(100 mg/ml) for 24 h, followed by counting of bacterial
colonies and CFU evaluation.
Statistical analysis
The χ2 and Fisher’s exact tests were used to analyze the
association of mutations with clinical characteristics. All
p values were calculated based on a two-tailed hypoth-
esis. p <0.05 was considered statistically significant.
Results
RBM5 expression was significantly decreased in primary
lung adenocarcinoma
To assess the expression of RBM5 mRNA and protein in
human lung adenocarcinoma, we performed RT-PCR
and Western blot analysis on 30 pairs of primary lung
tumor versus adjacent non-tumor tissues. Our results
showed that the expression of both RBM5 mRNA and
protein was decreased in lung tumor compared to that
in the non-tumor counterpart (Figure 1C, χ2 = 2.814,
P < 0.05; Figure 1D, χ2 = 2.963, P < 0.05). When the bands
were quantitatively compared, expression of RBM5
mRNA was found to be lower in tumor compared to the
non-tumor counterpart in the majority of the paired
samples (except in 9 of the 30 patients, Figure 1A, C).
Figure 3 Effect of RBM5 overexpression on A549 cells proliferation. A549 cells were transfected with pcDNA3.1 or pcDNA3.1-RBM5 plasmids
for up to 24 h and 48 h. Afterward, cell growth was observed under microscopy (A) and evaluated by MTT assay (B). The data are presented as
the ratio compared to the control (control = 100%). Data shown are means ± SD of three separate experiments. * p< 0.05, ** p<0.01 indicate
significant difference as compared to the control.
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the expression of RBM5 protein was found to be lower
in tumor compared to the non-tumor counterpart in the
majority of the paired samples (except in 7 of the 30
patients, Figure 1B, D). Our result confirms the previous
finding that RBM5 expression was decreased in human
lung adenocarcinoma tissues compared to that in the
corresponding non-tumor tissues.
Overexpression of RBM5 inhibits A549 cells proliferation
To further determine the relationship between RBM5
gene and tumor growth, we performed the proliferation
assay in A549 cells to explore the effect of RBM5 over-
expression on proliferation of tumor cells. We transi-
ently transfected A549 cells with pcDNA3.1-RBM5, then
the expression level of RBM5 in A549 cells was deter-
mined by RT-PCR and Western blot, presented in
Figure 2. MTT assays were performed at 24 h and 48 h,respectively, after the transfection. Results showed that
there was a significant inhibition of cell proliferation in
RBM5-overexpressing A549 cells compared to that in
controls (Figure 3 A, B). Along with the extension of the
time, the inhibition rate was increased.
Overexpression of RBM5 induces apoptosis in A549 cells
We next explored the mechanisms underlying growth in-
hibition by RBM5. To determine the contribution of cell
death induced by RBM5, we employed FCM to detect
apoptotic cells, which are characterized by phosphatidyl
serine (PS) translocation on the outer cell membrane.
Cells were double-stained with AnnexinV and PI after
48 h transfection. Representative raw FCM data are as
follows: Cells transfected with RBM5 showed a higher
proportion of early and late apoptosis (13.41% and
18.28%) as compared to the control cells (4.01% and
7.94%), respectively (Figure 4). The early and the late
Figure 4 Effect of RBM5 overexpression on apoptosis in A549 cells. A549 cells were harvested at 48 h after transfection. PS flip to the outer
nuclear membrane was monitored by staining cells with FITC-conjugated Annexin V, which binds to the PS and PI (A). Data are presented as a
flow cytomter dot plot. Q1, live cells; Q2, early apoptotic cells; Q3, late apoptotic cells; Q4, necrosis cells. (B) The representative data of FCM with
Annexin V and PI staining for detecting apoptotic cells are shown in control and RBM5 transfected groups. *Significant difference as compared to
the control (p< 0.05).
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regions, respectively. The necrotic cells were located in
the Q4 region. The result suggested that overexpression
of RBM5 significantly increased apoptosis in lung can-
cer cells.RBM5 overexpression is associated with alteration of
apoptosis-related genes
To further study the possible molecular mechanisms
underlying RBM5-induced cell apoptosis, we next exam-
ined the expression of some apoptosis-related genes in-
cluding Bcl-2, caspase-3, caspase-9 and PARP. We
observed that the expression of Bcl-2 protein was
decreased significantly when RBM5 was overexpressed,
while the expression of cleaved caspase-3, caspase-9 and
PARP proteins was significantly increased in the RBM5overexpressing cells as compared to that in the control
cells. Accordingly, the expression of caspase-9 protein was
slightly decreased in RBM5 overexpressing cells as com-
pared to that in the control cells, while the expression of
caspase-3 and PARP had no significant difference in either
group (Figure 5). This result again suggested that RBM5,
by decreasing Bcl-2 expression, could induce caspase-3,
caspase-9, PAPP cleavage and promoted apoptosis.Assessment on transfection of the attenuated Salmonella
typhi Ty21a carrying plasmids into A549 xenograft BALB/
c nude mice
To further test our hypothesis, the model of A549 xeno-
graft was established as described in Materials and
methods. At the 28th day after implantation, the tumor-
bearing mice were inoculated with bacteria carrying the
Figure 5 Effect of RBM5 on the expression of apoptosis-related genes in A549 cells. Cellular proteins were extracted from A549 cells
transfected with pcDNA3.1 or pcDNA3.1-RBM5 plasmids for 48 h. (A) Expression of RBM5, Bcl-2, caspase-3, cleaved caspase-3, caspase-9, cleaved
caspase-9, PARP and cleaved PARP were determined by Western blot. (B) Quantitative data from A. *Significant difference as compared to the
control (p< 0.05).
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mouse. To ensure that attenuated Salmonella typhi
Ty21a carrying plasmids preferentially localized in the
tissue, we monitored the kinetics of bacterium distribu-
tion in the xenograft tumor and different organs of the
tumor-bearing area at certain post-injection times
(Figure 6A). On day 3 (72 h) after injection, bacteria
could be found predominantly in the tumors compared
to other organs (Figure 6 A, B; p < 0.05), which indicated
the tumor-targeting character of attenuated Salmonella
typhi Ty21a. We found that the concentration of bac-
teria gradually decreased in the tumors, however, which
was found decrease or vanish significantly in other
organs on day 7 after injection (Figure 6 A, C). We con-
cluded that the bacteria could be accumulated in the
tumors in the course of treatment since we injected the
mice every 7 days from day 28 to day 42. Quantitative
analysis of the bacteria by CFUs as described in Materi-
als and methods (Figure 6B and C) confirmed the pre-
dominant distribution of bacteria in the tumor tissues.
Suppression of tumor growth by RBM5 in A549 xenograft
tumors and the alteration of apoptosis-related genes
The potential therapeutic effect on lung adenocarcinoma
xenograft growth by RBM5 was examined in tumor-
bearing mice treated with bacteria carrying RBM5 plasmid(Figure 7A). Dynamic tumor growth was monitored from
day 7 to day 42 after injection. We showed that, while the
sizes of the tumor xenografts between RBM5 and control
groups were similar before day 28, the growth of tumor
xenografts in the mice treated with RBM5 decreased after
the 28th day (Figure 7B). In addition, the weight of the
tumor xenografts from mice treated with RBM5 became
significantly lighter than that in the control group at the
42nd day when the mice were killed (Figure 7C). This re-
sult suggested that accumulative and stable expression
of RBM5 in A549 xenograft BALB/c nude mice signifi-
cantly retarded the tumor growth rate in vivo. More-
over, we set up a novel animal model using BALB/c
nude mice treated with attenuated Salmonella as a vec-
tor carrying plasmids to determine RBM5 function
in vivo.
To further explore whether it possesses the same mo-
lecular mechanisms underlying RBM5 functions on both
in vitro and in vivo, we examined the expression of
Bcl-2 and caspase-3 proteins in A549 xenograft. Simi-
larly, we found that the expression of Bcl-2 was signifi-
cantly decreased in A549 xenograft BALB/c nude mice
treated with RBM5 as compared to the control mice,
while the expression of cleaved caspase-3 was signifi-
cantly increased in RBM5-treated mice (Figure 8). This
result, consistent with the cell line study, suggested again
Figure 6 Assessment of tumor-preferable distribution of the bacteria. Tissue samples from the lung tumor xenografts, liver, lung, spleen,
heart and kidney of three tumor-bearing mice treated with bacteria carrying vector control were collected for bacterial distribution analysis.
Tissue (100 mg) from either tumors or each organ in 3 ml of PBS was homogenized well, and the homogenized tissue was plated onto Luria-
Bertani agar. The result was observed after 14 h. (A) Representative images of the plates planted with different tissues at day 3 (72 h) and day 7
(148 h) after bacterial injection. T, tumor xenograft; Li, liver; Lu, lung; S, spleen; H, heart; K, kidney. (B) and (C) Quantitative analysis of the bacterial
counts by CFU per gram of tissue at day 3 (B) and day 7 (C) after bacterial injection. *Significant difference in tumor xenograft group as
compared to other group (p< 0.05).
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of caspase-3, promoted apoptosis and suppressed the
tumor growth in vivo.
Discussion
There is increasing evidence suggesting that RBM5 plays
an important role in lung cancer occurrence and develop-
ment; nevertheless, there are few studies reporting the
RBM5 expression in lung cancer tissues and tumor cell
lines. In a very small cohort of eleven specimens, it was
observed that the six tumor samples with the most signifi-
cantly reduced RBM5 mRNA levels were of the squamous
type [11,15,16] whereas three of the nine with less signifi-
cantly reduced RBM5 mRNA levels were adenocarcin-
omas. The one tumor sample with no change in RBM5
mRNA expression compared to its non-tumor tissue was
an adenocarcinoma, while the one tumor sample that had
more RBM5 mRNA than its non-tumor tissue was a largecell carcinoma [11,15]. These results suggest that RBM5
gene expression is related to histologic subtype in NSCLC.
Moreover, RBM5 mRNA was downregulated in spontan-
eously developing human tumors such as human
schwannomas [24] and in transformed cells, such as
ras-transformed Rat-1 rat embryonic fibroblastic cells
[25]. Consistent with the above findings, our study con-
firms previous study in terms of the RBM5 expression
in lung adenocarcinoma and further suggests that
RBM5 plays a critical role in the occurrence and devel-
opment in lung carcinoma.
RBM5 is a putative tumor suppressor. The gene encodes
a number of alternative RNA splice variants with differ-
ing abilities to enhance, sensitize or suppress apoptosis
[13,17,26-28]. Thus, it is likely that the ability to modu-
late apoptosis is central to the putative tumor suppres-
sor activity of RBM5. Despite increasing evidence
showing the activity of the apoptotic modulator of
Figure 7 RBM5 inhibits tumor growth in vivo. Tumor-bearing mice were treated with attenuated Salmonella carrying pcDNA3.1 or pcDNA3.1-
RBM5 by injection two times (on day 28 and 35). (A) Comparison of tumor size in two groups on day 42 after implantation. (B) Tumor growth
curve. Tumor sizes were measured two times every week from day 7 to 42 after implantation. (C) Tumor wet weights were measured when the
mice were killed on day 42 after implantation. *Significant difference as compared to the control (p< 0.05); #Significant difference as compared to
the control (p< 0.01).
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anism is still largely unknown. In order to further con-
firm the fact and investigate the potential molecular
mechanism underlying the tumor suppressive activity of
RBM5, we observed the effects of RBM5 on A549 cell
growth and apoptosis with RBM5 overexpression. Our
results showed that RBM5 overexpression significantly
inhibited cell proliferation and induced early and late
apoptosis in A549 cells, which was associated with
downregulation of Bcl-2 and upregulation of cleavedFigure 8 Effect of RBM5 on the expression of apoptosis-related gene
from tumor tissues treated with attenuated salmonella carrying pcDNA3.1
RBM5, Bcl-2, caspase-3 and cleaved caspase-3 were determined by Western
to the control (p< 0.05).caspase-3, -9 and PARP. Similar studies were reported
in other groups [8,17,28]. Oh et al.. showed that the cyc-
lin A and phosphorylated RB levels were decreased,
whereas expression of Bax protein was increased in
RBM5-transfected A549 cells; this led to changes in the
mitochondrial membrane potential, cytochrome c release
into the cytosol, and enhanced caspase-9 and caspase-3
activities, thereby inducing apoptosis [8]. Note that Bcl-2
expression had no change in Oh’s study; a possible reason
for the difference between our and this study might be thes in A549 xenograft BALB/c nude mice. Proteins were extracted
or attenuated salmonella carrying pcDNA3.1-RBM5. (A) Expression of
blot. (B) Quantitative data from A. *Significant difference as compared
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strated that overexpression of RBM5 enhanced p53-
mediated inhibition of cell growth and colony formation
in different cell lines. Expression of RBM5 augmented
p53 transcriptional activity in reporter gene assays and
resulted in increased mRNA and protein levels for en-
dogenous p53 target genes [19]. In all, our study con-
firms previous findings and demonstrates the activity of
the apoptotic modulator associated with RBM5.
In order to confirm our in vitro results, the lung
adenocarcinoma transplantation in vivo model was made
by injecting A549 cells onto the back of immunocom-
promised mice. Our results indicated that overexpres-
sion of RBM5 reduced the volume and weight of
transplanted lung tumors significantly. Through bacterial
distribution analysis, the characteristics of replicating
preferentially in tumor cells for the Salmonella typhi
Ty21a were identified. Previous study demonstrated that
Salmonella could be infected and preferentially accumu-
lated in the tumor xenograft in vivo, with a tumor/nor-
mal tissue-retaining ratio of approximately 1,000:1 [29].
Attenuated Salmonella typhi Ty21a is a facultative an-
aerobic bacterium that was capable of replicating prefer-
entially in tumor cells and was used for developing
proteins therapeutic to several different tumors [30-33].
We showed that a large amount of the Salmonella typhi
Ty21a still remained in the tumor tissues at the later
stage of treatment. This suggested that expression of
RBM5 protein was maintained and continued to be ef-
fective in suppressing tumor growth throughout the
whole process. The attenuated Salmonella typhi Ty2la
bacteria approaches in our study demonstrated an im-
portant role of RBM5 in inhibition of tumor growth.
Moreover, our in vivo results further confirmed the mo-
lecular mechanism underlying RBM5-induced apoptosis
might be by means of inhibiting expression of bcl-2 and
triggering the cleavage of caspases. In our in vivo assay,
the transplant tumor model was established using A549
cells in both the experimental and control groups. When
compared with Oh et al..’s study [8], the benefit of accu-
mulative and relatively stably maintained expression of
RBM5 in tumors in our in vivo study could better reflect
the potential therapeutic role of RBM5 in effective inhib-
ition of lung cancer cell growth. Thus, our in vivo study,
which demonstrated the anti-tumor effect of RBM5
significantly, may be more convincing and promising,
which demonstrated the anti-tumor effect of RBM5
significantly.
Conclusion
In summary, our results showed that RBM5 significantly
inhibits tumor growth and induces apoptosis of lung
cancer cells by reducing the expression of Bcl-2, subse-
quently inducing the expression of cleaved caspase-3,cleaved caspase-9 and cleaved PARP. More importantly,
accumulative and stable expression of RBM5 in tumors
significantly inhibits the tumor growth rate in vivo. Fi-
nally, RBM5 might be used as a potential biomarker or
target for lung cancer diagnosis and chemotherapy.
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